Iovance Biotherapeutics (Iovance Biotherapeutics) ROCE %

: -67.77% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Iovance Biotherapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -67.77%.

Iovance Biotherapeutics ROCE % Historical Data

The historical data trend for Iovance Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-53.59

-51.40

-48.90

-63.28

-74.13

Iovance Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-82.40	-67.70	-62.63	-66.22	-67.77

Iovance Biotherapeutics ROCE % Calculation

Iovance Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-460.559	/	( ( (663.982 - 91.485)	+	(780.351 - 110.306) )	/ 2 )
	=	-460.559	/	( (572.497	+	670.045)	/ 2 )
	=	-460.559	/	621.271
	=	-74.13 %

Iovance Biotherapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-485.024	/	( ( (852.315 - 90.955)	+	(780.351 - 110.306) )	/ 2 )
	=	-485.024	/	( ( 761.36	+	670.045 )	/ 2 )
	=	-485.024	/	715.7025
	=	-67.77 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Iovance Biotherapeutics (NAS:IOVA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Iovance Biotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2LB:Germany 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Executives

Merrill A Mcpeak	director	PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wayne P. Rothbaum	director	C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Wendy L Yarno	director
Frederick G Vogt	officer: General Counsel	2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes	director	112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon	director
Ryan D Maynard	director	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky	officer: Chief Operating Officer	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin	officer: Chief Financial Officer	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg	officer: VP, Finance	C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf	officer: Chief Medical Officer	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris	officer: Chief Financial Officer	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis	director, officer: President and CEO	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085